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and Bangkok, Thailand.BACKGROUND The beneﬁts of catheter ablation for elderly
patients with atrial ﬁbrillation (AF) with respect to mortality and
stroke reductions remain unclear.
OBJECTIVE The purpose of this study was to evaluate the safety
and efﬁcacy, including long-term outcomes, of catheter ablation for
maintaining normal sinus rhythm (NSR) in elderly patients with AF.
METHODS We evaluated 587 elderly patients (ageZ75 years) with
AF. Of the 324 who were eligible for ablation, 261 (group 1)
underwent ablation guided by complex fractionated atrial electro-
gram. The remaining 63 patients (group 2) either declined or were
not suitable for ablation. The end-points were NSR, stroke, death,
and major bleeding.
RESULTS Two hundred sixteen patients (83%) remained in NSR
compared to only 14 group 2 patients (22%; mean follow-up 3 
2.5 years, P o.001). The 1- and 5-year survival rates for group 1
with NSR, group 1 with AF, and group 2 patients were 98% and
87%, 86% and 52%, and 97% and 42%, respectively (Po.0001).
NSR was an independent favorable parameter for survival (hazard
ratio [HR] 0.36; 95% CI, 0.02-0.63, p ¼ 0.0005), whereas older
age (HR 1.09, 95% CI 1.01–1.16, P ¼ .02) and depressed ejectionThis study was supported by Grants-in-Aid from Adventist Health Care
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unfavorable. Warfarin therapy was discontinued in 169 of the 216
group 1 patients (78%) who maintained NSR and had only 3%
5-year stroke/bleeding rates compared to 16% in group 2
(P o.001).
CONCLUSION Elderly patients with AF beneﬁt from AF ablation,
which is safe and effective in maintaining sinus rhythm and is
associated with lower mortality and stroke risks.
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ABBREVIATIONS AF ¼ atrial ﬁbrillation; AT ¼ atrial tachycardia;
CFAE ¼ complex fractionated atrial electrogram; CI ¼ conﬁdence
interval; EF ¼ ejection fraction; HR ¼ hazard ratio; IH ¼
intracranial hemorrhage; INR ¼ international normalized ratio;
IS ¼ ischemic stroke; LA ¼ left atrium; NSR ¼ normal sinus
rhythm; PVI ¼ pulmonary vein isolation; RF ¼ radiofrequency; TIA
¼ transient ischemic attack
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As the elderly population (age Z75 years) grows, so does
the burden of treating elderly patients with atrial ﬁbrillation
(AF).1–3 Physicians have long known that treating such
patients is a difﬁcult task because AF is associated with
increases in mortality and morbidity, especially stroke and
thromboembolic risks in the elderly.2,3 Treating the elderly
with AF remains a major therapeutic challenge for physi-
cians because antiarrhythmic drugs are not effective, and
they pose signiﬁcant risks.4,5 Although anticoagulation withwarfarin has proved to be effective in preventing ischemic
stroke in this population, it also imposes a signiﬁcant risk of
major bleeding complications, especially intracranial hem-
orrhage [IH].6,7
Catheter ablation has recently emerged as an important
therapeutic alternative to maintain normal sinus rhythm
(NSR) in patients with AF.8–11 However, the beneﬁt of
catheter ablation in elderly patients with AF has not been
clearly elucidated. The objective of this observational study
was to evaluate the safety and efﬁcacy of catheter ablation for
maintaining NSR in elderly patients with AF, as well as to
evaluate the long-term clinical outcomes after ablation.Methods
Study design
Our study is a retrospective analysis of prospectively
collected data, which consisted of patients who were Z75http://dx.doi.org/10.1016/j.hrthm.2014.09.049.
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patients who were mentally unstable; who had alcoholism,
myocardial infarction within 1 month of the study, terminal
disease, or left atrial (LA) thrombus; who could not commit
to participate in scheduled outpatient follow-up; or who
preferred recently approved new anticoagulation drugs
because of the small sample size and short follow-up period.
All patients signed informed consent, which was approved
by the Institutional Review Board.
Mapping and ablation of AF
After stopping antiarrhythmic drugs for 5 half-lives or after
3 months with amiodarone, the patients underwent non-
ﬂuoroscopic electroanatomic mapping with the CARTO
system (Biosense Webster Inc, Diamond Bar, CA) as
previously described.9
All maps were created during AF and associated atrial
anatomy with complex fractionated atrial electrogram
(CFAE) areas. Targeting these CFAE areas, radiofrequency
(RF) ablations were delivered until AF was converted to
NSR or all CFAE areas were ablated. When areas with
CFAE were completely eliminated but the atrial arrhythmias
(organized atrial ﬂutter or atrial tachycardia [AT]) persisted,
they were subsequently mapped and ablated (occasionally in
conjunction with ibutilide 1–2 mg intravenously over 10–20
minutes). If the arrhythmias were not successfully reverted to
NSR, external cardioversion was performed.
RF applications were delivered with a maximal temper-
ature of 551C to 601C at the catheter tip (4-mm and 8-mm
NaviStar catheters). The 4-mm and 8-mm NaviStar catheters
were used until February 2006, when an irrigated-tip
NaviStar catheter became available. Since then, we exclu-
sively used the latter catheter for AF ablation. RF energy was
delivered in the range between 20 and 50 W for 60 seconds,
with maximal temperature at 431C; however, at the posterior
wall, RF was limited to maximal power of 35 W for only
20 seconds.
Clinical end-points
The primary end-points were maintenance of NSR, stroke or
transient ischemic attack (TIA), major bleeding, systemic
emboli, and all-cause mortality. All patients were followed
up in our arrhythmia clinic every 3 months. For patients who
had no implantable device, clinical success of ablation was
determined based on patient clinical symptoms in conjunc-
tion with follow-up ECG every 3 months, 3-week continuous
ECG monitoring before discontinuation of warfarin at
3 months after ablation and yearly thereafter unless the
patient had recurrent symptoms, in which case continuous
monitoring was commenced. The “blanking period” for
arrhythmia recurrence assessment was 3 months from the
date of the last ablation.
For patients with implanted devices in our study, assess-
ment of AT/AF burden could be performed accurately and
continuously. AT/AF burden was deﬁned as the total
duration of all spontaneous AT/AF episodes divided by thecorresponding follow-up time. Device follow-up time was
the time between device interrogations that occurred on
consecutive follow-up visits.
Anticoagulation management
Anticoagulation management for our patients has changed
over time. From 2001 to 2007, patients were treated with
warfarin to maintain an international normalized ratio (INR)
between 2 and 3 for at least 3 weeks before the ablation, as
well as postablation. Warfarin was discontinued 4 days
before the ablation. Patients with persistent or permanent
AF were given enoxaparin sodium 1 mg/kg subcutaneously
every 12 hours before the ablation. Both warfarin and
enoxaparin were restarted immediately after the procedure,
but enoxaparin was discontinued 3 days later.
At the beginning of 2008, we changed our approach to
non-stopped anticoagulation and continued oral warfarin
(INR 2–3). Heparin was also used during the procedure, with
the aim of keeping the activated clotting time between 300
and 350 seconds.
If the patient remained in NSR 3 months after ablation,
warfarin was discontinued, and aspirin, clopidogrel, or both
were arbitrarily and immediately prescribed. Patients who
developed recurrent AT/AF were restarted on warfarin if
their clinical recurrent AT/AF episodes lasted longer than 12
hours or their estimated cumulative AF duration of all
episodes averaged over the preceding 3 months was 460
minutes per day. The rationale for using a 12-hour or more
duration of AF as a cutoff to resume warfarin treatment was
based on our previous studies involving high-risk AF
patients.11
The outcomes of the ablations, based on device inter-
rogation, were classiﬁed as follows. AT/AF response I
(Online Supplemental Figure 1) was deﬁned as total sup-
pression of AT/AF (r1% AT/AF burden/day). AT/AF
response II (Online Supplemental Figure 2) was deﬁned as
partial suppression (1%–5% AT/AF burden per day and
o12-hour duration in any given episode. AT/AF response
III (Online Supplemental Figure 3) was deﬁned as insufﬁ-
cient suppression (45% AT/AF burden per day or Z12
hours in any given episode).
Statistical and data analysis
Data are reported as mean and standard deviation (SD) for
continuous variables and as proportion (%) for categorical
variables. Median and quartiles are presented for skewed
data. Characteristics of patients were compared using the
Student t test or Mann–Whitney test for continuous varia-
bles, and the Fisher exact test or χ2 test for categorical data
where applicable. Kaplan–Meier analysis was used to assess
patient mortality, stroke rates, and major event end-points
among different stratiﬁed groups. The estimates were eval-
uated with the log-rank test. Multivariate analysis of
inﬂuences of factors, including NSR, congestive heart fail-
ure, hypertension, ejection fraction (EF)r40%, and female
gender, were performed using Cox proportional hazards
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compare AF burdens after ablation.
Results
Five hundred eighty-seven elderly patients were evaluated
for AF treatment with ablation. Of those patients, 263 were
not offered catheter ablation for their AF and were excluded
from the study; 137 (52%) of the excluded patients could not
commit to attend regular follow-up and frequent continuous
ECG monitoring; 46 (17.5%) refused to adhere to an
anticoagulation treatment program and 23 (9%) patient
wanted to stay with a new anticoagulation treatment; 29
(11%) had dementia and severe cognitive disorder; 19 (7%)
had previous disabling strokes; and 9 (3.5%) had LA
thrombus. The remaining 324 were eligible and committed
to follow-up in our arrhythmia clinic: 261 (group 1) under-
went AF ablation but 63 (group 2) did not; 54 declined the
procedure and chose medical therapy with a rate control
regimen but continued follow-up in the arrhythmia clinic; 5
preferred pacemaker/implantable cardioverter-deﬁbrillator
therapy ﬁrst; and 4 needed emergency surgery, precluding
the ablation procedure. Of the 261 group 1 patients, 147
(56%) had only 1 session, 88 (34%) had 2 sessions, 18 (7%)
had 3 sessions, and 8 (3%) had 4 sessions. Mean procedure,
ﬂuoroscopic, and cumulative RF times were 136  40
minutes, 7.9  3.4 minutes, and 40  19 minutes,
respectively. Patient characteristics are summarized in
Table 1. Importantly, study patients from both groups
committed to follow-up in our arrhythmia clinic, which
allowed us to accurately assess key clinical outcomes such as
death, strokes, and bleeding complications.
One hundred one patients had implantable devices.
However, we included only 92 patients who had a device
that could assess AT/AF burden: 75 from group 1 (ablation)Table 1 Comparison of demographics between group 1 (ablation) and
Ablation
Age (years) 79.3  4 (median 78)
Age Z80 years 90 (34%)
Female 93 (37%)
Type of AF
Paroxysmal 71 (27%)
Persistent 61 (23%)
Long-standing persistent 129 (49%)
Risk factors
Hypertension 139 (53%)
Previous stroke 28 (11%)
Congestive heart failure 44 (17%)
Coronary disease 57 (21%)
Cardiomyopathy 16 (6%)
Valvular disease 38 (15%)
Diabetes 34 (13%)
CHADS2 2.1  1.1 (median 2)
AF duration (months) 48  54 (median 36)
EF (%) 51  13 (median 55)
EF o40% 54 (21%)
Left atrial size (mm) 47  6
Values are given as no. (%) or (mean  SD) unless otherwise indicated.
AF ¼ atrial ﬁbrillation; EF ¼ ejection fraction.and 17 from group 2 (no ablation). The remaining 9 patients
who had devices without AT/AF burden assessment features
were excluded.
Effects of AF ablation on maintaining sinus rhythm
After mean follow-up of 3  2.5 years (range 1–10 years)
from the last ablation session, 216 of the 261 group 1 patients
(83%) maintained NSR and 45 did not. In contrast, only 14
of the 63 group 2 patients (22%) maintained in NSR (P
o.0001). Only 27 group 1 patients (10%) were on sotalol,
and none were on class I antiarrhythmic agents or amiodar-
one. When clinical characteristics were compared between
patients who maintained NSR after the last ablation vs those
who did not, results revealed a higher incidence of long-
standing persistent AF (46% vs 69%, P ¼ .005), longer AF
duration (42 42 months vs 77 86 months, P ¼ .01), and
larger LA size (46 6 mm vs 51 5 mm, Po.0001) in the
group that failed ablation.
Effects of ablation on AT/AF burden
Of the 75 group 1 patients with implantable devices, 64
(85%) had persistent or long-standing persistent AF, as
indicated by AF burden average over the preceding 3 months
before the ﬁrst ablation, and 11 had paroxysmal AF (15%).
Similarly, 15 of the 17 group 2 patients (88%) with
implantable devices had persistent or long-standing persis-
tent AF; the remaining 2 patients (12%) had paroxysmal AF.
The effects of ablation on AF burden in patients with an
implantable device (group 1 vs group 2) is shown in
Figure 1. During the ﬁrst month after ablation, only 24%
of group 1 patients achieved AT/AF response I (total
suppression,o1% AT/AF burden/day) and 52% at 3 months
(not shown in Figure 1). After this 3-month blanking period,
however, the effect of ablation on total suppression of AT/group 2 (no ablation) patients
No ablation P value
79  4 (median 78)
23 (37%) .8
28 (44%) .2
18 (29%) .72
17 (27%)
28 (44%)
31 (49%) .67
6 (10%) 1
13 (21%) .47
13 (21%) .87
5 (8%) .58
2 (3%) .01
6 (10%) 1
2  1.1 (median 2)
43  52 (median 30)
49  14 (median 54)
16 (28%) .38
46  5
Figure 1 Comparison of 4-year atrial tachycardia/atrial ﬁbrillation (AT/AF) burden between group 1 and group 2 patients with an implantable device. Each
circle represents AT/AF burden of individual patients at a given time point. Red indicates group 1; green indicates group 2.
Figure 2 Kaplan–Meier curve demonstrating improved survival in
patients who remained in sinus rhythm after atrial ﬁbrillation (AF) ablation
from all-cause mortality compared to patients who remained in AF
ﬁbrillation after ablation and patients who did not undergo catheter ablation.
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21% of group 1 patients failed to respond to ablation and the
remaining 5% of group 1 patients had their AF burden
partially suppressed (AT/AF response II).
Catheter ablation drastically reduces AF burden, and the
effect is long-lasting (Figure 1). This occurs despite the fact
that many patients had recurrences of asymptomatic AT/AF
episodes, which were of short duration and did not require
medical intervention.
Effects of ablation and sinus rhythm on survival
Thirty-four deaths (13%) occurred in group 1: 10 cardiovas-
cular (29%), 3 stroke-related (9%; 1 with ischemic stroke
[IS] and 2 with IH), and 21 noncardiovascular (62%). In
contrast, 16 deaths (25%) occurred in group 2 : 7 cardio-
vascular (44%), 4 stroke-related (25%; 3 IS and 1 IH), and 5
noncardiovascular (31%). Annual mortality rates were 4%
and 9.8% for groups 1 and 2, respectively (P o.0001).
Figure 2 shows better survival rates in group 1 patients
who maintained NSR after ablation compared to group 1
patients who remained in AF after ablation and group 2
patients; however, the beneﬁt on survival rate did not appear
until after 2 years of follow-up. The 1- and 5-year survival
rates for group 1 with NSR, group 1 with AF, and group 2
patients were 98% and 87%, 86% and 52%, and 97% and
42%, respectively (P o.0001).
NSR was an independent factor associated with better
survival (hazard ratio [HR] 0.36, 95% conﬁdence interval
[CI] 0.2–0.63, P ¼ .0005). Older age and low EF (o40%)
were independent predictors of mortality (HR 1.09, 95% CI
1.01–1.16, P ¼ .02; and HR 2.38, 95% CI 1.28–4.44, P ¼
.006, respectively), whereas other factors such as female
gender, congestive heart failure, and hypertension were not
independently associated with increases in mortality in our
patient population (Table 2).Effects of ablation on stroke rate and long-term
anticoagulation management
Of the 261 group 1 patients, 169 of the 219 (77%) patients
who maintained NSR stopped warfarin and switched to
either aspirin or clopidogrel or both. In contrast, 9 of the 63
group 2 patients (14%) stopped warfarin (P o.0001). The
majority of our patients who continued on warfarin were
managed in our coagulation clinic; in approximately 15% of
the patients the primary care physician adjusting their
warfarin doses. However, only 64% were able to maintain
INR consistently in the range of 2–3.
Figure 3 summarizes the stroke/bleeding incidence of
groups 1 and 2 according to their ﬁnal rhythms and CHADS2
scores. Regardless of the CHADS2 score and warfarin
treatment, patients with NSR did very well, with a very
low incidence of stroke or bleeding. In group 1 patients who
discontinued warfarin, 3 had IS, 1 had TIA, and 1 had major
Table 2 Multivariate cox regression analysis of hazard ratio of
key risk variables
Hazard
ratio
95% Conﬁdence
interval P value
Normal sinus rhythm 0.36 0.2–0.63 .0005
Congestive heart
failure
1.38 0.72–2.65 .33
Age 1.09 1.01–1.16 .02
Ejection fraction
r40%
2.38 1.28–4.44 .006
Hypertension 1.28 0.71–2.29 .42
Female 1.31 0.73–2.335 .40
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warfarin, 1 had IH and the other had severe gastrointestinal
bleeding. In contrast, 4 of the 9 patients who failed ablation
and remained in AT/AF but did not continue to take warfarin
(poor compliance and refusal) had IS. For group 2 patients, 8
who remained in AT/AF and on warfarin experienced stroke
(6 IS, 1 TIA, and 1 IH), and 1 patient had subdural
hematoma. One patient in group 2 who was in NSR and
off warfarin had gastrointestinal bleeding.
Figure 4 shows no difference in stroke/bleeding incidence
between patients who were on vs those who were offFigure 3 Stroke/bleeding incidence of both group 1 and 2 patients according to
tachycardia; IH ¼ intracranial hemorrhage; IS ¼ ischemic stroke; NSR ¼ normalwarfarin. Patients who maintained NSR had a very low
stroke rate regardless of warfarin treatment. Group 1 patients
with NSR and off warfarin had 5-year stroke/bleeding rates
of only 3% compared with 16% for group 2 patients
(P o.001). The stroke/bleeding rates in group 1 patients
who stayed in NSR after ablation remained low, even after 5-
year follow-up and even without anticoagulation.
Procedure complications
Acute complications
Of the 261 group 1 patients, 2 (0.8%) had IS; both occurred
with an 8-mm-tip catheter and before continuous oral anti-
coagulation for the ablation procedures was implemented.
Four patients (1.5%) had hemopericardium, 10 (4%) had
major bleeding at the groin sites, and 3 (1%) had pulmonary
edema 24 hours after the procedure.
Thirty-day major events
One death due to IH occurred in the 30-day period after the
ablation procedure. Seventeen patients had to be rehospital-
ized for a major event: 7 groin complications (4 pseudoa-
neurysms and 3 severe bleeding at the groin site), 7
symptomatic AT, 3 urinary tract infection, and 2 high fever
successfully treated with broad-spectrum antibiotics.their ﬁnal rhythms and CHADS2 scores. AF ¼ atrial ﬁbrillation; AT ¼ atrial
sinus rhythm; SH ¼ subdural hematoma; TIA ¼ transient ischemic attack.
Figure 4 Multiple overlay Kaplan–Meier stroke/bleeding–free survival
curves among 5 groups of patients: (1) successful ablation–normal sinus
rhythm (NSR) on no warfarin, (2) successful ablation–NSR on warfarin, (3)
unsuccessful ablation–atrial ﬁbrillation (AF) on no warfarin, (4) unsuccess-
ful ablation–AF on warfarin, and (5) no ablation–NSR on warfarin
(group 2).
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Our ﬁndings show that maintaining long-term NSR in this
population by catheter ablation targeting CFAE is feasible in
approximately 80% of patients, although a signiﬁcant
number of patients required more than 1 procedure. Because
one-third of our patients had a continuous monitoring device
to detect daily AT/AF burden, we were able to accurately and
precisely assess the effects of ablation on recurrent AT/AF
and their consequences in a large portion of our study
patients. Ablation signiﬁcantly reduced AT/AF burden,
despite the fact that the majority of the patients with
implantable devices had either persistent or long-standing
persistent AF: 74% of the patients had virtually no AF
burden, and 5% had a low AF burden (o1% per day). The
effects of ablation on NSR maintenance are long-lasting;
although some of the patients who initially had 0% AT/AF
burden later developed brief episodes of AT/AF, most were
asymptomatic after a longer follow-up period. However, the
subclinical brief late recurrent AT/AF episodes in these
patients did not have a clinical impact on survival or stroke
rates, as discussed later.Effects of sinus rhythm on stroke rate and need for
anticoagulation
In our entire study population, the overall stroke/bleeding
rate was quite low, even for those with higher CHADS2
scores (Figure 3), even though the majority of patients
stopped anticoagulation and switched to aspirin, clopidogrel,
or both. The lower stroke rate in our elderly patients was
clearly attributed to the fact that the majority of the patients
were in NSR, and anticoagulation levels were monitored
closely in those who remained in AF.
Our study demonstrates that maintaining NSR in elderly
AF patients is associated with a lower stroke rate. Our
ﬁndings also suggest that oral anticoagulation may not be
needed in elderly patients after their AF is suppressed by
ablation. This supposition, based on our data, undoubtedly
will create controversy. Because there are well-established
data that AF patients often have asymptomatic AF episodesthat can precipitate strokes,12 one must be careful in
declaring that AF is cured and that patients, especially
elderly patients, are no longer at risk for stroke. As evidenced
by our patients with an implantable device, recurrent
subclinical atrial tachyarrhythmia episodes can occur, even
though the patients had virtually no AT/AF burden initially
after successful ablation. However, most of the late recurrent
episodes did not reach the threshold established from our
previous study of stroke risk necessitating anticoagulation
treatment,11 suggesting that in our patient population, after
ablation, the shorter duration of AT/AF burden is an
acceptable reason for not resuming anticoagulation. Also,
the majority of recurrent atrial tachyarrhythmias (sympto-
matic or asymptomatic) after CFAE ablation may not
necessarily have been true AF episodes but rather atrial
ﬂutter or AT, which may have a lower embolic risk, possibly
because of partially preserved atrial contractility.
Sinus rhythm begets better survival
Patients who maintained NSR after ablation had a better
survival rate than did those who failed ablation and remained
in AF and those who did not undergo AF ablation. Interest-
ingly, the survival beneﬁt of NSR became apparent 2 years
postablation and certainly will raise the question: Could the
group 1 patients who failed AF ablation and the group 2
patients who had more advanced heart disease or unrecog-
nized risk factors have attributes that prevented them from
maintaining NSR and unfavorably inﬂuenced their overall
survival as well? Multivariate analysis and Cox regression
analysis showed that NSR was associated with a 64%
reduction in mortality (HR 0.36, 95% CI 0.02–0.63, P ¼
.0005), whereas relatively older age and EF o40% were
independent predictors of a poor prognosis, and hypertension
and female gender had little effect. It is noteworthy that for
our patients we did not prescribe class I antiarrhythmic
agents or amiodarone, which are known to inﬂuence survival
rates in patients with AF. Thus, one may be tempted to
speculate that the better survival outcomes in patients who
maintained NSR were not offset by the unwanted effects of
these drugs on total mortality.
Comparison with previous studies
To date, few observational studies reported in the literature
have assessed the safety and efﬁcacy of AF ablation in
elderly patients with AF. In 2 separate reports, Bunch et al13
and Santangeli et al14 reported favorable outcomes of
pulmonary vein isolation (PVI) with and without additional
ablation lines in octogenarians with AF, with a success rate
of maintaining NSR ranging between 70% and 87%,
including repeat ablations (mean follow-up of 1 year). Both
reports found no difference in success rates between AF
patients who were younger than 80 years and those Z80
years of age.
Blandino et al15 compared catheter ablation vs antiarrhyth-
mic drugs in a subset of persistent AF patients (470 years
old) and found that ablation (including a second procedure)
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antiarrhythmic drugs (76% vs 46%, P o.001). However,
unlike our study and those of Bunch et al13 and Santangeli
et al,14 Blandino and colleagues also reported a substantial risk
of embolic complications associated with the procedure (3.3%
periprocedural cerebral thromboembolisms). The reasons for
the difference in procedure-related complications in the
studies by Blandino et al and other investigators are unclear
and possibly are multifactorial, including anticoagulation
management (stopping warfarin before the procedure) and
different ablation techniques and tools. At any rate, the overall
results of these studies and ours are in agreement with regard
to the effectiveness of catheter ablation in maintaining sinus
rhythm. However, our approach is different from that used in
the other studies, which performed PVI and adjunct therapy,
whereas we targeted substrates guided by CFAE mapping.
Clearly, further studies, including randomized clinical trials to
evaluate catheter ablation in the elderly subset, are warranted
to better assess its values and limitations.Study limitations
Our study is not a randomized trial or a multicenter study. One
could criticize the possibility of selection bias and unmeasured
confounding variables in our study patients, raising the
possibility that the patients in our study who responded to
ablation and maintained NSR had more favorable risk proﬁles
than did the other groups of patients in our study. However,
we believe that this was not the case because our study
patients wereZ75 years old and had signiﬁcant comorbidities
with very high CHADS2 scores, and the majority of our
patients had either persistent or long-standing persistent AF.
In fact, we believe our study comprises 1 of the sickest AF
populations compared with other studies.13–15
One may question whether our criteria of stopping warfarin
treatment are robust and appropriate for all AF patients with
high risk of strokes. This question clearly cannot be answered
without additional studies to support our current ﬁndings.
Nevertheless, our study is unique in that we had a signiﬁcant
number of patients with implantable AT/AF burden devices,
which veriﬁed that asymptomatic AF indeed occurred but was
not associated with an increased risk of stroke.
Finally, CFAE ablation technique without PVI is not
universally used by most centers and has not been well
replicated by others,8 which raises the concern that it may not
be applicable to most centers that perform PVI with or
without hybrid ablations (linear lesions, CFAE ganglionic
plexi ablation). Although this concern is valid, we believe that
our ﬁndings are solid because the number of study patients
and the duration of follow-up were more than adequate and
even extended. Our study was not designed to determine
whether our ablation technique was superior to others but
merely to demonstrate that if NSR is maintained in an elderly
population, then mortality and stroke rates are reduced. At
any rate, the overall results of our study are similar to those of
other studies, which performed PVI and adjunct ablation
treatment but had a relatively smaller sample size and ashorter follow-up period, with respect to the effectiveness of
catheter ablation in maintaining NSR.13–15
Conclusion
Our ﬁndings show that CFAE ablation of AF is effective in
maintaining NSR in elderly AF patients. In our patient
population, the beneﬁts of being in NSR are remarkable with
respect to stroke and mortality reduction. After successful
ablation, warfarin treatment can be safely discontinued
without an increased risk of cerebrovascular accidents. This
beneﬁt is long-lasting and important in the management of
elderly patients who are not always ideal candidates for
anticoagulation.
Appendix
Supplementary data
Supplementary data associated with this article can be found
in the online version at http://dx.doi.org/10.1016/j.hrthm.
2014.09.049.References
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One of the major therapeutic challenges for physicians in the 21st century is how to best treat elderly patients with atrial
ﬁbrillation (AF). Currently, rate control and anticoagulation are the mainstays of AF treatment for this population. Although
catheter ablation of AF has gained wider acceptance in young patients with paroxysmal AF, the beneﬁts and risks of AF
ablation in the elderly are unclear. We evaluated 587 elderly patients (Z75 year old, median age 78 years) with AF. Of the
324 patients who were eligible for ablation, 261 (group 1) underwent ablation guided by complex fractionated atrial
electrogram (CFAE). The remaining 63 patients (group 2) either declined or were not suitable for ablation. The end-points
were NSR, stroke, death, and major bleeding. After mean follow-up of 3 years, we found that 216 patients (83%) remained
in NSR compared to only 14 group 2 patients (22%) and NSR maintenance was associated with mortality and stroke
reduction. Our observational study presents new ﬁndings that catheter ablation by targeting CFAE has a beneﬁcial role in
elderly patients with AF, with relatively low complication rates; however, it requires multiple procedures in a signiﬁcant
number of patients. Our data suggest that the beneﬁts of catheter ablation may outweigh the procedure risks and may
improve treatment outcomes of elderly patients with AF. Multicenter randomized controlled trials are needed to conﬁrm or
deny our ﬁndings before AF ablation can become the primary treatment in this subset of elderly patients with AF.
